Ocugen said its gene therapy program for geographic atrophy, a form of vision loss, will move into a phase 3 trial after it reported mixed results in a smaller study. The company framed the phase-to-phase progression as part of continued clinical evaluation, with the phase 3 trial designed to better establish efficacy and safety. The update arrives after investor sensitivity to gene therapy outcomes and reinforces the long-running effort to find disease-modifying approaches for advanced macular degeneration pathways. For the field, phase 3 progression—despite mixed earlier signals—indicates ongoing confidence in the therapeutic approach and trial design. Ocugen did not provide full additional data in the excerpt, but the direction of travel will draw attention from both retinal specialists and investors tracking gene therapy risk in ophthalmology.